Suppr超能文献

基于普鲁兰多糖和聚(β-氨基)酯的核壳纳米粒用于肝癌靶向基因和化疗药物共递送

Core-shell nanoparticles based on pullulan and poly(β-amino) ester for hepatoma-targeted codelivery of gene and chemotherapy agent.

机构信息

Tianjin Cancer Institute and Hospital, Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Research Center of Basic Medical Science & School of Pharmacy, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), Tianjin Medical University , No. 22 Qixiangtai Road, Heping District, Tianjin 300070, People's Republic of China.

出版信息

ACS Appl Mater Interfaces. 2014;6(21):18712-20. doi: 10.1021/am504203x. Epub 2014 Oct 27.

Abstract

This study designs a novel nanoparticle system with core-shell structure based on pullulan and poly(β-amino) ester (PBAE) for the hepatoma-targeted codelivery of gene and chemotherapy agent. Plasmid DNA expressing green fluorescent protein (pEGFP), as a model gene, was fully condensed with cationic PBAE to form the inner core of PBAE/pEGFP polycomplex. Methotrexate (MTX), as a model chemotherapy agent, was conjugated to pullulan by ester bond to synthesize polymeric prodrug of MTX-PL. MTX-PL was then adsorbed on the surface of PBAE/pEGFP polycomplex to form MTX-PL/PBAE/pEGFP nanoparticles with a classic core-shell structure. MTX-PL was also used as a hepatoma targeting moiety, because of its specific binding affinity for asialoglycoprotein receptor (ASGPR) overexpressed by human hepatoma HepG2 cells. MTX-PL/PBAE/pEGFP nanoparticles realized the efficient transfection of pEGFP in HepG2 cells and exhibited significant inhibitory effect on the cell proliferation. In HepG2 tumor-bearing nude mice, MTX-PL/PBAE/pEGFP nanoparticles were mainly distributed in the tumor after 24 h postintravenous injection. Altogether, this novel codelivery system with a strong hepatoma-targeting property achieved simultaneous delivery of gene and chemotherapy agent into tumor at both cellular and animal levels.

摘要

本研究设计了一种基于普鲁兰多糖和聚(β-氨基)酯(PBAE)的具有核壳结构的新型纳米粒子系统,用于肝癌靶向基因和化疗药物的共递药。表达绿色荧光蛋白(pEGFP)的质粒 DNA 作为模型基因,与阳离子 PBAE 充分缩合形成 PBAE/pEGFP 聚电解质复合物的内核。甲氨蝶呤(MTX)作为模型化疗药物,通过酯键键合到普鲁兰多糖上,合成 MTX-PL 聚合物前药。然后,MTX-PL 被吸附在 PBAE/pEGFP 聚电解质复合物的表面上,形成具有经典核壳结构的 MTX-PL/PBAE/pEGFP 纳米粒子。MTX-PL 还被用作肝癌靶向部分,因为它与人肝癌 HepG2 细胞过度表达的去唾液酸糖蛋白受体(ASGPR)具有特异性结合亲和力。MTX-PL/PBAE/pEGFP 纳米粒子在 HepG2 细胞中实现了 pEGFP 的高效转染,并表现出对细胞增殖的显著抑制作用。在 HepG2 荷瘤裸鼠中,静脉注射后 24 h,MTX-PL/PBAE/pEGFP 纳米粒子主要分布在肿瘤中。总之,这种具有强肝癌靶向性的新型共递药系统在细胞和动物水平上实现了基因和化疗药物的同时递送到肿瘤部位。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验